SCHEMBL3700822

SCHEMBL3700822

C=CCNC(=O)CC1C(=O)N(CCc2ccc(Cl)cc2Cl)CC(=O)N1Cc1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 6/20 0.47
CASP3 P42574 6/20 0.47
CASP9 P55211 6/20 0.47
CYCS P99999 6/20 0.47
P2RX7 Q99572 4/20 0.42
TAAR1 Q96RJ0 1/20 0.41
ACHE P22303 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 2/20 0.37
MAPT P10636 2/20 0.37
KMT2A Q03164 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5956810 0.90 TAAR1 (0.48) APAF1CASP3CASP9CYCSP2RX7
SCHEMBL3696992 0.88 APAF1 (0.45) APAF1CASP3CASP9CYCSP2RX7
SCHEMBL3700926 0.87 APAF1 (0.48) APAF1CASP3CASP9CYCSP2RX7
SCHEMBL3698673 0.87 APAF1 (0.50) APAF1CASP3CASP9CYCSP2RX7
SCHEMBL3695106 0.87 APAF1 (0.45) APAF1CASP3CASP9CYCSP2RX7
SCHEMBL3703338 0.86 APAF1 (0.49) APAF1CASP3CASP9CYCSP2RX7
SCHEMBL3701794 0.86 APAF1 (0.47) APAF1CASP3CASP9CYCSP2RX7
SCHEMBL3696929 0.85 APAF1 (0.44) APAF1CASP3CASP9CYCSP2RX7
SCHEMBL3695847 0.85 APAF1 (0.44) APAF1CASP3CASP9CYCSP2RX7
SCHEMBL3697539 0.85 APAF1 (0.52) APAF1CASP3CASP9CYCSP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040701-B2 Apaf-1 inhibitor compounds LABORATORIOS SALVAT, S.A. (ES) 2015-05-26 US disclosed
US-9040701-B2 Apaf-1 inhibitor compounds LABORATORIOS SALVAT, S.A. (ES) 2015-05-26 US disclosed
US-9040701-B2 Apaf-1 inhibitor compounds LABORATORIOS SALVAT, S.A. (ES) 2015-05-26 US disclosed
EP-2460798-A2 APAF-1 INHIBITOR COMPOUNDS Laboratorios SALVAT, S.A. (ES) 2012-06-06 EP disclosed
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS LABORATORIOS SALVAT, S.A. (ES) 2012-05-17 US disclosed
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS LABORATORIOS SALVAT, S.A. (ES) 2012-05-17 US disclosed
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS LABORATORIOS SALVAT, S.A. (ES) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122868-A1 APAF-1 INHIBITOR COMPOUNDS APAF1, API5, AIFM1 APAF1 1/4885CASP3 13/4885CASP9 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.